Treatment with nifedipine — Competitive Intelligence Brief

Treatment with nifedipine (Treatment with nifedipine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

phase 3 Calcium channel blocker L-type calcium channels Cardiovascular Small molecule

Target snapshot

Treatment with nifedipine (Treatment with nifedipine) — Laboratorios Richmond S.A.C.I.F.. Nifedipine works by inhibiting the L-type calcium channels in smooth muscle cells, leading to vasodilation and a decrease in blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Treatment with nifedipine TARGET	Treatment with nifedipine	Laboratorios Richmond S.A.C.I.F.	phase 3	Calcium channel blocker	L-type calcium channels
Verapamil + paroxetine	Verapamil + paroxetine	University of California, Irvine	marketed	SSRI + calcium channel blocker combination	P-glycoprotein (MDR1/ABCB1), L-type calcium channels
Nifedipine/Telmisartan	Nifedipine/Telmisartan	Bayer	marketed	Calcium channel blocker + Angiotensin II receptor blocker combination	L-type calcium channels; AT1 angiotensin II receptor
Treatment R	Treatment R	Boryung Pharmaceutical Co., Ltd	marketed	Calcium channel blocker	L-type calcium channels
Magnesium sulfate IV	Magnesium sulfate IV	University of Liege	marketed	Electrolyte supplement / anticonvulsant	NMDA receptor, L-type calcium channels
irbesartan, amlodipine and hydrochlorothiazide	irbesartan, amlodipine and hydrochlorothiazide	Assistance Publique - Hôpitaux de Paris	marketed	Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
Nicardipine + Verapamil + Nitroglycerin	Nicardipine + Verapamil + Nitroglycerin	Peng Roc Chen, MD	marketed	Combination antihypertensive/antianginal (calcium channel blockers + nitrate)	L-type calcium channels (nicardipine, verapamil); soluble guanylate cyclase (nitroglycerin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
3. Ain Shams University · 1 drug in this class
4. Bioprojet · 1 drug in this class
5. Bristol-Myers Squibb · 1 drug in this class
6. GlaxoSmithKline · 1 drug in this class
7. Handok Inc. · 1 drug in this class
8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class